Related Experiment Videos
Review article: future indications for terlipressin therapy
1Laboratoire d'Hémodynamique Splanchnique et de Biologie Vasculaire, INSERM U-481, Hôpital Beaujon, Clichy, France. lebrec@bichat.inserm.fr
Alimentary Pharmacology & Therapeutics
|September 1, 2004
Summary
Terlipressin, a vasoconstrictor, improves kidney function and survival in hepatorenal syndrome (HRS) patients. It also shows promise for liver transplant recipients and other critical conditions like endotoxic shock.
Area of Science:
- Pharmacology
- Nephrology
- Hepatology
Background:
- Hepatorenal syndrome (HRS) is a severe complication of advanced liver disease.
- Patients with HRS experience significant renal impairment and poor prognosis.
- Vasoconstrictor agents are explored to manage circulatory dysfunction in HRS.
Purpose of the Study:
- To evaluate the efficacy of terlipressin in treating hepatorenal syndrome (HRS).
- To assess the impact of terlipressin on renal function and survival rates in HRS patients.
- To explore terlipressin's potential in other critical conditions.
Main Methods:
- Review of studies investigating terlipressin in HRS treatment.
- Analysis of data on renal function improvement and survival rates.
- Examination of terlipressin's effects in related conditions.
Main Results:
- Terlipressin demonstrated beneficial effects on renal function in HRS patients.
- Treatment with terlipressin was associated with improved survival rates.
- Positive outcomes were observed in patients undergoing liver transplantation post-terlipressin treatment.
- Terlipressin showed potential in paracentesis-induced circulatory dysfunction and endotoxic shock.
Conclusions:
- Terlipressin is an effective treatment for hepatorenal syndrome, improving renal function and survival.
- Pre-transplant terlipressin therapy enhances survival for HRS patients undergoing liver transplantation.
- Terlipressin holds promise for managing other critical circulatory dysfunctions.